- Quintara Biosciences has acquired Laragen Sanger Sequencing, formerly operated by Transnetyx, effective 15 September 2025.
- The acquisition maintains uninterrupted service for existing customers while expanding Quintara’s operations across California.
Quintara Biosciences has completed the acquisition of Laragen Sanger Sequencing, reinforcing its strategic growth in California’s life sciences corridor. The deal, effective 15 September 2025, ensures continuity of service for Laragen’s existing customers.
All Sanger Sequencing services previously offered by Laragen—including DNA sequencing, microbial identification, and cell line identification—will continue without disruption. Quintara will retain the same team, instruments, and drop-box network, and will honour existing pricing arrangements.
“Los Angeles has always been a vital link between our Bay Area and San Diego operations. Strengthening our presence here not only connects our California network but also positions us to serve the entire West Coast with faster turnaround, expanded sequencing options, and greater operational resilience.”
Daniel Wang, CEO of Quintara Biosciences.
The acquisition also expands Quintara’s molecular biology and sequencing capabilities, supporting long-read and high-throughput sequencing applications. Sue Zhao, General Manager, added: “Integrating Laragen Sanger Sequencing Services enhances our throughput and reinforces our local sequencing infrastructure, enabling us to provide comprehensive solutions that bridge traditional Sanger workflows with advanced sequencing platforms.”
Transnetyx CEO Bob Bean welcomed the transition, noting that Quintara’s reputation and scientific expertise will provide a trusted partnership for Laragen’s longstanding research customers in Los Angeles.
